This interview has expired.
Click here to find stocks, with exciting stories, and management committed to maximizing shareholder value.
Special deals for our readers
Are you qualified for the Visa Black Card?
The World’s Most Prestigious and Versatile Credit Card. Apply Now!
Be a more profitable investor:
What’s Jim Cramer trading in his personal portfolio? Click here
Why are you still paying too much with Schwab, and and E-trade?? Step up to the #1 discount broker: TradeKing.
Find out why TradeKing.com was ranked #1 Discount Broker by SmartMoney Magazine two years running! (August 2006 & 2007).
LifeLock is the only Identity Theft Prevention Solution backed by a one-million dollar guarantee!Click here to get a 10% discount.
Click here to get access to powerful investing tools only available at Investor’s Business Daily.
Bob Butchofsky, CEO
QLT Inc. (QLT), is a global biopharmaceutical company engaged in the business of discovering, developing and commercialization of therapies. QLT has two commercial products, Visudyne and Eligard. Visudyne utilizes photodynamic therapy (PDT), to treat the eye disease known as wet age related macular degeneration (wet AMD), the cause of blindness in people over the age of 55 in North America and Europe. Visudyne is also used for the treatment of subfoveal choroidal neovascularization (CNV) due to pathologic myopia, or severe near-sightedness, and presumed ocular histoplasmosis or other macular diseases. The Eligard product line includes one, three, four and six month commercial formulations of Atrigel technology combined with leuprolide acetate.